Abstract
Tumour necrosis factor-alpha inhibitors (TNFi) increase the risk of reactivation of latent tuberculosis (TB). The objective of this review was to assess the risk of tuberculosis in patients receiving TNFi therapy and to compare the risks among the different anti-TNF agents. We searched the
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of the Royal College of Physicians of London
Paper Title
Journal
Date
